Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-Week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects With Moderate-to-Severe Plaque Psoriasis (AFFIRM)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2021
Price :
$35
*
At a glance
- Drugs Tepilamide-fumarate (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms AFFIRM
- Sponsors Dr Reddys Laboratories
- 09 Dec 2020 Status changed from active, no longer recruiting to completed.
- 24 Mar 2020 Planned End Date changed from 30 Jan 2020 to 30 Mar 2020.
- 24 Mar 2020 Planned primary completion date changed from 30 Jan 2020 to 30 Mar 2020.